Skip to main content
Clinical Trials/NCT01429870
NCT01429870
Withdrawn
Phase 4

A Phase IV, Randomized, Double Blind, Placebo Controlled, Single-center Study of the Impact of Topical Steroids on Narrow Band UVB (Ultraviolet B) and Dithranol Combination Treatment of Psoriasis (DIPSO)

University of Zurich1 site in 1 countryAugust 2011

Overview

Phase
Phase 4
Intervention
Steroid active treatment
Conditions
Psoriasis
Sponsor
University of Zurich
Locations
1
Primary Endpoint
Relapse 50% PASI after treatment, time to PASI 75% on treatment
Status
Withdrawn
Last Updated
7 years ago

Overview

Brief Summary

Objective(s):

(i) To assess the effect of adjunctive topical steroids in the combined treatment with UVBnb and dithranol on the remission time after therapy till a relapse of psoriasis defined as 50% loss of PASI (Psoriasis Area and Severity Index) improvement obtained through the antecedent treatment.

(ii) To assess the impact of adjuvant topical steroids in the combined treatment with UVBnb and dithranol on the clearing time of psoriasis lesions under therapy (PASI 75).

  • Trial with medicinal product

Detailed Description

(i) To assess the effect of adjunctive topical steroids in the combined treatment with UVBnb and dithranol on the remission time after therapy till a relapse of psoriasis defined as 50% loss of PASI (Psoriasis Area and Severity Index) improvement obtained through the antecedent treatment. (ii) To assess the impact of adjuvant topical steroids in the combined treatment with UVBnb and dithranol on the clearing time of psoriasis lesions under therapy (PASI 75). * Trial with medicinal product

Registry
clinicaltrials.gov
Start Date
August 2011
End Date
August 2016
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Steroid active treatment

Triamcinolone acetonide 0.1% in unguentum leniens topically

Intervention: Steroid active treatment

Vehicle

unguentum leniens topically

Intervention: Steroid active treatment

Outcomes

Primary Outcomes

Relapse 50% PASI after treatment, time to PASI 75% on treatment

Time Frame: 2 years

Relapse 50% PASI after treatment, time to PASI 75% on treatment

Study Sites (1)

Loading locations...

Similar Trials